Profund Advisors LLC Trims Stake in Teleflex Incorporated (TFX)

Profund Advisors LLC cut its position in Teleflex Incorporated (NYSE:TFX) by 24.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,748 shares of the medical technology company’s stock after selling 1,866 shares during the period. Profund Advisors LLC’s holdings in Teleflex were worth $1,194,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of TFX. First Trust Advisors LP grew its stake in shares of Teleflex by 22.9% in the 1st quarter. First Trust Advisors LP now owns 47,885 shares of the medical technology company’s stock valued at $9,277,000 after buying an additional 8,914 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Teleflex by 5.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,949 shares of the medical technology company’s stock valued at $1,152,000 after buying an additional 303 shares during the period. World Asset Management Inc grew its stake in shares of Teleflex by 6.0% in the 1st quarter. World Asset Management Inc now owns 2,841 shares of the medical technology company’s stock valued at $550,000 after buying an additional 162 shares during the period. UBS Asset Management Americas Inc. grew its stake in shares of Teleflex by 28.3% in the 1st quarter. UBS Asset Management Americas Inc. now owns 93,115 shares of the medical technology company’s stock valued at $18,039,000 after buying an additional 20,555 shares during the period. Finally, Karp Capital Management Corp acquired a new stake in shares of Teleflex in the 1st quarter valued at about $2,100,000. Institutional investors own 89.75% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.chaffeybreeze.com/2017/09/21/profund-advisors-llc-trims-stake-in-teleflex-incorporated-tfx.html.

In other Teleflex news, Director Stephen K. M.D. Klasko sold 200 shares of the company’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $208.41, for a total value of $41,682.00. Following the sale, the director now owns 8,080 shares in the company, valued at $1,683,952.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders sold 600 shares of company stock worth $125,652. Corporate insiders own 2.39% of the company’s stock.

Several analysts have recently commented on TFX shares. Zacks Investment Research upgraded Teleflex from a “hold” rating to a “buy” rating and set a $261.00 target price for the company in a research note on Tuesday, September 12th. Leerink Swann raised their target price on Teleflex from $215.00 to $220.00 and gave the company a “market perform” rating in a research note on Friday, June 9th. BidaskClub downgraded Teleflex from a “hold” rating to a “sell” rating in a research note on Tuesday, August 8th. Barclays PLC restated an “overweight” rating and issued a $253.00 target price (up from $230.00) on shares of Teleflex in a research note on Tuesday, September 12th. Finally, Needham & Company LLC restated a “buy” rating on shares of Teleflex in a research note on Friday, August 4th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $258.86.

Teleflex Incorporated (NYSE:TFX) opened at 236.86 on Thursday. The company has a 50-day moving average of $216.57 and a 200 day moving average of $205.08. The company has a market cap of $10.67 billion, a PE ratio of 45.30 and a beta of 1.05. Teleflex Incorporated has a 12 month low of $136.53 and a 12 month high of $240.93.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, August 3rd. The medical technology company reported $2.04 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.91 by $0.13. The business had revenue of $528.60 million for the quarter, compared to analysts’ expectations of $518.98 million. Teleflex had a net margin of 12.36% and a return on equity of 16.12%. The business’s revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.89 earnings per share. On average, equities analysts forecast that Teleflex Incorporated will post $8.28 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 15th. Shareholders of record on Tuesday, August 15th were issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date of this dividend was Friday, August 11th. Teleflex’s dividend payout ratio (DPR) is presently 26.00%.

Teleflex Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Institutional Ownership by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply